Senior Deals Analyst
Latest From Maureen Riordan
Ten $1bn+ alliances were penned in January. In the top alliance by deal value, Shanghai Argo Biopharmaceutical entered into exclusive collaboration with Novartis Pharma for two undisclosed Argo cardiovascular disease programs, one in Phase I and another in Phase I/IIa. Novartis gets an exclusive global license to develop and commercialize the Phase I program and also receives an option to potentially license compounds directed against up to two additional targets. For the Phase I/IIa program, Novartis gets an exclusive license worldwide except in Greater China. The deal could be worth up to $4.17bn for Argo.
During Q4, biopharma merger and acquisition deal value reached $63bn and drew in $75.4bn in potential deal value from alliances. Device company M&A values reached $4.8bn, while in vitro diagnostics and research tools players’ M&A activity totaled $3.4bn.
During the fourth quarter, biopharmas brought in an aggregate $13.1bn in financing and device company fundraising totaled $1.1bn; while in vitro diagnostic firms and research tools players raised $459m.
Six $1bn+ alliances were penned in December. In the top alliance by deal value, Biokin and its SystImmune subsidiary licensed Bristol Myers Squibb exclusive rights to develop and commercialize its cancer candidate BL-B01D1 worldwide, excluding Mainland China where SystImmune retains rights. BMS will pay $800m up front, up to $500m in contingent near-term payments, and up to $7.1bn in development, regulatory, and sales milestones, for a total potential consideration of up to $8.4bn.
Five $1bn+ alliances were penned in November. In the top alliance by deal value, Cellectis and AstraZeneca entered into a joint research collaboration agreement to accelerate the development of next-generation therapeutics in areas of oncology, immunology and rare diseases. The deal could be worth up to $2.4bn. AstraZeneca will leverage Cellectis’ proprietary gene editing technologies and manufacturing capabilities to design novel cell and gene therapy candidate products. A total of 25 genetic targets have been exclusively reserved for AstraZeneca, which holds an option to license exclusive global rights to develop and sell up to 10 of the targets, to be exercised before IND filing.
Nine $1bn+ alliances were penned in October. Topping the list was a potential $22bn deal between Daiichi Sankyo and Merck for the global development and commercialization of Daiichi’s DXd antibody drug conjugate candidates patritumab deruxtecan, ifinatamab deruxtecan and raludotatug deruxtecan.